Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $68,387.20 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 2,485 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $27.52, for a total transaction of $68,387.20. Following the completion of the sale, the insider now owns 75,294 shares in the company, valued at $2,072,090.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Wednesday, September 18th, Catriona Yale sold 3,871 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.56, for a total value of $106,684.76.
• On Tuesday, September 10th, Catriona Yale sold 637 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total value of $16,676.66.
• On Friday, August 23rd, Catriona Yale sold 8,851 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $243,668.03.
• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $143,052.00.

Akero Therapeutics Stock Up 0.3 %

Shares of NASDAQ:AKRO opened at $28.08 on Friday. The company has a quick ratio of 24.89, a current ratio of 24.89 and a debt-to-equity ratio of 0.04. The business’s 50 day moving average is $26.33 and its 200 day moving average is $23.96. The stock has a market cap of $1.94 billion, a P/E ratio of -8.78 and a beta of -0.26. Akero Therapeutics, Inc. has a 52-week low of $11.25 and a 52-week high of $51.24.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.09. Sell-side analysts predict that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Analysts Set New Price Targets

AKRO has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Akero Therapeutics in a research note on Thursday, June 20th. Wolfe Research began coverage on Akero Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating for the company. Finally, HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a research note on Tuesday. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Akero Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $41.13.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. lifted its position in shares of Akero Therapeutics by 2,366.0% in the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after purchasing an additional 1,183 shares during the period. Quarry LP lifted its holdings in Akero Therapeutics by 40.0% during the fourth quarter. Quarry LP now owns 1,750 shares of the company’s stock worth $41,000 after buying an additional 500 shares during the period. Quest Partners LLC bought a new stake in Akero Therapeutics during the 4th quarter valued at $75,000. Headlands Technologies LLC increased its holdings in shares of Akero Therapeutics by 253.5% in the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock valued at $107,000 after acquiring an additional 3,024 shares during the period. Finally, Ameritas Investment Partners Inc. raised its position in shares of Akero Therapeutics by 20.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after acquiring an additional 1,030 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.